Skip to content
DataLookout
Menu

NCT07933211

A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.

StatusNot Yet Recruiting
PhasePhase 2/3
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 1 with changes below, 1 re-verified with no change.

  1. Study First Submitted

Endpoints

Primary

Part 1 & Part 2: Achievement of Revised Composite Response Index in Systemic Sclerosis (rCRISS)-25
Timeframe: At Week 52
Part 1 & Part 2: Number of Participants Experiencing Adverse Events
Timeframe: Up to 112 Weeks

Secondary (9)

Part 1 & Part 2: Change from Baseline in Forced Vital Capacity (FVC) (mLs) in participants with interstitial lung disease (ILD) at Baseline
Part 1 & Part 2: Absolute change from Baseline in percent-predicted FVC in subjects with ILD at Baseline
Part 1 & Part 2: Change from Baseline in modified Rodnan skin score (mRSS) in all participants with mRSS score of > 10 at Baseline
Part 1 & Part 2: Improvement from Baseline in each of the following 3 components of the rCRISS-25 evaluated separately: FVC , mRSS and Health Assessment Questionnaire Disability Index (HAQ-DI)
Part 1 & Part 2: Change from Baseline in joint pain as assessed by the SSc Daily Diary
Show 4 moreShow less
Part 1 & Part 2: Change from Baseline in the Scleroderma Skin Patient Reported Outcome (SSPRO) physical effects domain
Part 1 & Part 2: Change from Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
Part 1 & Part 2: Improvement from Baseline in each of the following 2 components of the rCRISS-25 evaluated separately: PGA and CGA
Part 1 & Part 2: Absolute change from Baseline in percent-predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) (corrected for hemoglobin [Hb]) in participants with interstitial lung disease (ILD) at Baseline

Arms and interventions

Part 1: Double Blind Placebo Controlled Arm 1Experimental

Participants are randomized to receive Dose 1: ABBV-2294 (combination of ABBV-722 and upadacitinib)

Part 1: Double Blind Placebo Controlled Arm 2Experimental

Participants are randomized to receive Dose 2: ABBV-2294 (combination of ABBV-722 and upadacitinib)

Part 1: Double Blind Placebo Controlled Arm 3Experimental

Participants are randomized to receive ABBV-722

Part 1: Double Blind Placebo Controlled Arm 4Experimental

Participants are randomized to receive upadacitinib

Part 1: Double Blind Placebo Controlled Arm 5Experimental

Participants are randomized to receive placebo

Drugs: ABBV-722, Upadacitinib, Placebo for ABBV-722, Placebo for Upadacitinib